This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| NF-κB | |
|---|---|
| Name | NF-κB |
| Organism | Homo sapiens |
NF-κB is a family of transcription factors central to inducible gene expression in response to stress, pathogens, and inflammatory stimuli. Discovered through studies on viral oncogenesis and immune activation, these proteins coordinate signal-dependent transcriptional programs that affect cell survival, proliferation, and innate and adaptive responses. Studies across molecular biology, immunology, and clinical research highlight NF-κB as a nexus connecting pathogen recognition, cytokine signaling, and oncogenic transformation.
NF-κB was defined through biochemical purification and functional assays in laboratories studying Rudolf Virchow, Howard Temin, and viral regulators such as Human T-lymphotropic virus 1 and Epstein–Barr virus. Early work intersected with research on transcriptional regulation by groups at institutions including Cold Spring Harbor Laboratory, Max Planck Society, and National Institutes of Health. NF-κB activity integrates receptors like Toll-like receptor 4, Tumor necrosis factor receptor 1, and B-cell receptor signaling modules studied in cell lines derived from projects at Rockefeller University and Salk Institute. Its discovery influenced fields ranging from Oncogene research to clinical trials at centers such as Mayo Clinic and Johns Hopkins Hospital.
The NF-κB family comprises related subunits encoded by genes characterized in genomic projects led by Human Genome Project consortia and annotated by groups at European Bioinformatics Institute. Canonical mammalian subunits include RelA (p65), RelB, c-Rel, p50 (NFKB1), and p52 (NFKB2). Each member contains an N-terminal Rel homology domain characterized structurally in studies from Max Planck Institute of Biochemistry and modeled using methods developed at European Molecular Biology Laboratory. Rel proteins form homo- and heterodimers whose DNA-binding specificity was mapped in experiments by laboratories affiliated with Cold Spring Harbor Laboratory and Harvard Medical School. Inhibitory IκB proteins (IκBα, IκBβ, IκBε) contain ankyrin repeats characterized in structural studies at University of Cambridge and Stanford University. Processing of p100 to p52 involves proteolytic mechanisms delineated in studies reported by teams at University of California, San Francisco and Yale University.
Canonical activation follows receptor engagement by ligands such as Interleukin-1 or Lipopolysaccharide leading to recruitment of adaptor proteins (MyD88, TRIF) and kinases including IRAKs and TAK1, characterized in signaling networks studied at University of California, San Diego and Massachusetts Institute of Technology. The IκB kinase (IKK) complex—IKKα, IKKβ, and NEMO (IKKγ)—was defined in biochemical work from Institut Pasteur and University of Tokyo. Non-canonical activation via NF-κB–inducing kinase (NIK) and IKKα mediates p100 processing downstream of receptors like CD40 and BAFF receptor, analyzed by consortia at Fred Hutchinson Cancer Research Center and Dana-Farber Cancer Institute. Post-translational regulation includes phosphorylation, ubiquitination by E3 ligases such as TRAF family members investigated at Memorial Sloan Kettering Cancer Center, and deubiquitination by enzymes studied at Max Planck Institute for Biology of Ageing.
NF-κB controls expression of cytokines (e.g., Tumor necrosis factor, Interleukin-6), chemokines, adhesion molecules, and anti-apoptotic factors characterized in immunology programs at Imperial College London and Weizmann Institute of Science. In innate immunity, NF-κB is activated downstream of pattern recognition receptors including NOD2 and RIG-I, with implications explored in work from Karolinska Institutet and Pasteur Institute. In adaptive immunity, NF-κB regulates B-cell development via B-cell lymphoma 2 family interactions and T-cell activation through co-stimulatory molecules such as CD28, topics pursued at University of Oxford and University of Cambridge. NF-κB also interfaces with transcriptional regulators like STAT3 and p53, and chromatin modifiers studied in laboratories at Broad Institute and Whitehead Institute.
Aberrant NF-κB signaling contributes to chronic inflammation, autoimmune disorders, and cancer. Constitutive NF-κB activation is implicated in Diffuse large B-cell lymphoma, Multiple myeloma, and solid tumors examined in cohort studies at Memorial Sloan Kettering Cancer Center and Mayo Clinic. Mutations in pathway components (e.g., NFKBIA, NFKB2, CARD11) are linked to immunodeficiencies and lymphoproliferative diseases reported by teams at Johns Hopkins University and Hospital for Sick Children (Toronto). NF-κB also contributes to metabolic inflammation in conditions studied at University of Copenhagen and neuroinflammation investigated at University College London in contexts like Alzheimer's disease and Parkinson's disease.
Efforts to modulate NF-κB include small-molecule inhibitors of IKKβ developed in pharmacology programs at Novartis and Pfizer, proteasome inhibitors such as bortezomib used clinically at MD Anderson Cancer Center, and biologics targeting upstream cytokines like anti-TNF agents pioneered by researchers at University of North Carolina at Chapel Hill and Karolinska University Hospital. Gene therapy and RNAi approaches were tested in translational studies at NIH Clinical Center and biotechnology firms including Amgen. Natural product modulators from screens at institutions such as University of Tokyo and University of California, Berkeley provided leads that entered trials at centers like Cleveland Clinic.
NF-κB activity is assayed by electrophoretic mobility shift assays (EMSA) refined at Cold Spring Harbor Laboratory, chromatin immunoprecipitation (ChIP) protocols standardized by groups at European Molecular Biology Laboratory, reporter gene assays employed across laboratories at Stanford University, and imaging of nuclear translocation using confocal systems from manufacturers used at Max Planck Society. Proteomic identification of post-translational modifications relied on mass spectrometry platforms developed at Max Planck Institute for Biophysical Chemistry and bioinformatics pipelines from European Bioinformatics Institute. Knockout and transgenic mouse models produced by facilities at Jackson Laboratory and CRISPR-based perturbations from initiatives at Broad Institute remain central to mechanistic studies.
Category:Transcription factors